Exclusive Summary

• Targets a massive, high-demand market of over 200 million global patients suffering from chronic kidney disease linked to type 2 diabetes (T2D-CKD) and heart failure.
• With the innovator's core patent expiring around 2029, filing to the US FDA in 2026 secures a first-wave generic advantage, empowering clients with Day-1 launch opportunities.
• Highly recommended as a cornerstone therapy by top KDIGO and ADA guidelines, creating robust global demand for affordable generic alternatives that relieve payer burdens.
• Supported by stringent FDA cGMP compliance, this product bridges premium regulatory quality with significant manufacturing cost efficiencies, ensuring high margins for global distributors.